![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » KDx Diagnostics Earns CE Mark for Bladder Cancer Test
KDx Diagnostics Earns CE Mark for Bladder Cancer Test
California-based KDx Diagnostics has received a CE mark for URO17, its urine-based test for bladder cancer.
The noninvasive urine test can greatly reduce, if not eliminate, the need for an expensive in-bladder camera procedure, the company said.
Bladder cancer is among the most prevalent cancers worldwide and has a high recurrence rate that requires frequent retesting.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct